Anna Berglind

2.4k citations
12 papers · 1.5k · 3 hit papers · h-index 9

Impact in

  • Rheumatology top 0.5%
    • Systemic Lupus Erythematosus Research
  • Immunology top 5%
    • T-cell and B-cell Immunology
    • Atherosclerosis and Cardiovascular Diseases
    • Immune Cell Function and Interaction
    • interferon and immune responses

Papers in

    • Systemic Lupus Erythematosus Research 5
    • Respiratory viral infections research 1
    • Hepatitis B Virus Studies 1

Anna Berglind

12 papers receiving 1.5k citations

Anna Berglind's Hit Papers

Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials 2023 · 175 citations
1750+2+4Years since publication250500750

Peers

Anna Berglind
Comparison fields: 5 of 56
  • Rheumatology 989
  • Immunology 573
  • Radiology, Nuclear Medicine and Imaging 306
  • Hepatology 72
  • Nephrology 50
Replace L Rönnblom with:
L Rönnblom Sweden
Juan Carlos Mejía United States
Beulah Ji United States
Omid Zamani United States
Juanita Romero‐Díaz Mexico
Dana Tegzová Czechia
Tenshang Joh United States
Cecile Grootscholten Netherlands
Ana Malvar Argentina
Zakera Shums United States
Anna Berglind relative to L Rönnblom Sweden L Rönnblom's profile →
Citations per field
00.5×10×16.9×
L Rönnblom · 1×
Citations per year

Countries citing papers authored by Anna Berglind

Since Specialization
Citations

This map shows the geographic impact of Anna Berglind's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Berglind with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Berglind more than expected).

Fields of papers citing papers by Anna Berglind

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Berglind. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Berglind. The network helps show where Anna Berglind may publish in the future.

Co-authors

The 25 scholars most cited alongside Anna Berglind, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Anna Berglind Line = papers co-authored together Anna Berglind links everyone, so they are left out of the graph.

All Works

12 of 12 papers shown
#Work
1
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
Hit paper breakdown →
2019842
2
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
Hit paper breakdown →
2019313
3
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials
Hit paper breakdown →
2023175
4 201864
5 201430
6 201826
7 202016
8 201810
9 20208
10 20206
11 20173
12 20211

About Anna Berglind

Anna Berglind is a scholar working on Rheumatology, Epidemiology, Statistics and Probability, Pediatrics, Perinatology and Child Health and Oncology, having authored 12 papers that have together received 1.5k indexed citations. Recurring topics across this work include Systemic Lupus Erythematosus Research (5 papers), Statistical Methods in Clinical Trials (2 papers), Respiratory viral infections research (1 paper), Health Systems, Economic Evaluations, Quality of Life (1 paper), Cytokine Signaling Pathways and Interactions (1 paper), Healthcare Policy and Management (1 paper), Advanced Causal Inference Techniques (1 paper) and Hepatitis B Virus Studies (1 paper). The work is most often cited by research in Rheumatology (989 citations), Immunology (573 citations), Radiology, Nuclear Medicine and Imaging (306 citations), Hepatology (72 citations) and Nephrology (50 citations). Anna Berglind has collaborated with scholars based in Sweden, United States and United Kingdom. Frequent co-authors include Raj Tummala, Eric F. Morand, Philip Z. Brohawn, Ian N Bruce, Richard Furie, Lilia Pineda, Anca Askanase, Sang‐Cheol Bae, Christophe Richez and Yoshiya Tanaka. Their work appears in journals such as Annals of the Rheumatic Diseases, The Lancet Rheumatology, Antimicrobial Agents and Chemotherapy, Pharmaceutical Statistics and The Lancet Child & Adolescent Health.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact